Edition:
United States

Bayer AG (BAYGn.DE)

BAYGn.DE on Xetra

107.55EUR
17 Nov 2017
Change (% chg)

€-0.35 (-0.32%)
Prev Close
€107.90
Open
€107.85
Day's High
€108.70
Day's Low
€107.40
Volume
2,044,567
Avg. Vol
1,840,156
52-wk High
€123.90
52-wk Low
€86.03

Latest Key Developments (Source: Significant Developments)

PeptiDream announces discovery collaboration agreement with Bayer AG
Thursday, 16 Nov 2017 03:14am EST 

Nov 16 (Reuters) - PeptiDream Inc <4587.T>:Says it announced today that it has entered into a multi-target discovery collaboration with Germany-based Bayer AG.Under the terms of the agreement, it would receive an undisclosed upfront payment and research funding and is eligible to receive preclinical, clinical, and commercialization milestone payments potentially totaling up to $1.11 billion (124.5 billion yen) .In addition, it is eligible to receive royalties on sales of any products that arise from the collaboration .  Full Article

Bayer may terminate Loxo agreement if Larotrectinib is unapproved
Tuesday, 14 Nov 2017 07:58am EST 

Nov 14 (Reuters) - Loxo Oncology :Agreement with Bayer includes standstill provision preventing Bayer from acquiring 5 percent or more of co's voting securities​.Loxo says Bayer may terminate agreement if co gets CRL from U.S. Food and Drug agency with respect to Larotrectinib - SEC filing​.Bayer may terminate agreement if co does not get marketing approval for Larotrectinib by December 31, 2018​.  Full Article

Bayer, Loxo Oncology form partnership to develop, commercialise cancer drugs​
Tuesday, 14 Nov 2017 07:00am EST 

Nov 14 (Reuters) - Bayer Ag :Says it and loxo oncology to develop and commercialize two novel oncology therapies selectively targeting genetic drivers of cancer​.Says alliance to ‍target genetic drivers of cancer larotrectinib (loxo-101) and loxo-195 target tropomyosin receptor kinase (trk) fusion proteins​.Says ‍first filing for larotrectinib is planned in u.s. In late 2017 or early 2018, with eu filing expected in 2018.​.Says ‍loxo oncology will receive an upfront payment of usd 400 million and is eligible for usd 450 million in milestone payments​.Says ‍additional usd 200 million in milestone payments upon loxo-195 regulatory approvals and first commercial sale events in certain major markets.​.Says ‍will share development costs on a 50/50 basis.​.Says ‍bayer will lead ex-u.s. Regulatory activities, and worldwide commercial activities.​.Says ‍in u.s., where bayer and loxo oncology will co-promote products, parties will share commercial costs and profits on a 50/50 basis.​.Says ‍bayer will pay loxo oncology tiered double-digit percentage royalties on future net sales outside of u.s. And u.s. And ex-u.s. Sales milestones totaling usd 500 million.​.  Full Article

Loxo Oncology announces development and commercialization partnership with Bayer for cancer drugs
Tuesday, 14 Nov 2017 07:00am EST 

Nov 14 (Reuters) - Loxo Oncology Inc :Loxo Oncology announces global development and commercialization partnership with Bayer for larotrectinib and LOXO-195.Loxo Oncology Inc - ‍Loxo Oncology and Bayer to co-promote in U.S. with a 50/50 profit share; Bayer to commercialize RoW​.Loxo Oncology Inc - ‍under terms of agreement, Loxo Oncology will receive a $400 million upfront payment​.Loxo Oncology Inc - deal includes ‍up to $1.55 billion in upfront, regulatory, and commercial milestones​.Loxo Oncology - co eligible for $450 million in milestone payments upon larotrectinib approvals, first commercial sale events in some markets​.Loxo Oncology - co also eligible for additional $200 million in payments upon LOXO-195 approvals, first commercial sale events in some markets​.Loxo Oncology - ‍outside of U.S., ​Bayer will pay co royalties on sales, sales milestones totaling $475 million for larotrectinib & LOXO-195.  Full Article

CRISPR and Casebia collaborate with CureVac on mRNA for gene-editing programs
Monday, 13 Nov 2017 05:00am EST 

Nov 13 (Reuters) - CRISPR Therapeutics AG :CRISPR Therapeutics and Casebia collaborate with CureVac on mRNA for gene-editing programs.‍Under terms, CureVac will develop novel Cas9 mRNA constructs with improved properties for gene editing applications​.‍In exchange, CureVac will receive an upfront payment and research funding ​.CRISPR Therapeutics-‍CureVac to also be eligible to receive development, commercial milestones, royalties on commercialized products from collaboration​.  Full Article

Russian watchdog says Bayer-Monsanto deal poses risks to competition
Thursday, 9 Nov 2017 02:51am EST 

Nov 9 (Reuters) - Russia's Federal Anti-Monopoly Service (FAS) says::Bayer's <<>> planned takeover of U.S. seed maker Monsanto <<>> could create significant risks to competition on the Russian market;.The deal is likely to result in the bigger company sharply strengthening its position on the Russian market and becoming dominant, which will create high entry barriers for other companies;.The proposed solutions include Bayer sharing breeding technologies and giving access to digital farming data;.FAS has pushed back the deadline for the deal review by three months..Source link: http://bit.ly/2AnNJMyFurther company coverage: [BAYGn.DE] MON.N.  Full Article

Bayer says FDA accepts BLA filing for treatment of Hemophilia A
Monday, 30 Oct 2017 09:00am EDT 

Oct 30 (Reuters) - Bayer AG :Bayer - ‍U.S. FDA accepted co's BLA filing for bay94-9027 for treatment of Hemophilia A in adults and adolescents 12 years of age and over​.  Full Article

Bayer says no capital increase this year
Thursday, 26 Oct 2017 05:08am EDT 

Oct 26 (Reuters) - Bayer :CFO says no capital increase this year, we first want sufficient certainty about regulatory approval of Monsanto deal.  Full Article

Basf says seeking to strengthen ag business further
Tuesday, 24 Oct 2017 03:55am EDT 

Oct 24 (Reuters) - BASF :CEO says will look to strengthen agriculture business further after Bayer <<>> deal.CFO says impact on adjusted EBIT from hurricanes was about 50 million eur in Q3, will be about 30-50 million in Q4.  Full Article

Bayer files for Japanese approval of extended half-life Hemophilia A compound
Tuesday, 17 Oct 2017 03:00am EDT 

Oct 17 (Reuters) - Bayer AG :Submits its extended half-life Hemophilia A compound for marketing authorization in Japan​.Says ‍pivotal studies with BAY94-9027 showed that bleed protection was achieved with extended dosing intervals​.  Full Article

BRIEF-PeptiDream announces discovery collaboration agreement with Bayer AG

* Says it announced today that it has entered into a multi-target discovery collaboration with Germany-based Bayer AG